The CO2RE® System for Vulvar Lichen Sclerosus

Not Applicable

Completed

Conditions: Vulvar Lichen Sclerosus

Interventions: Device: The CO2RE® System

Registration Number: NCT04148651

Lead Sponsor: Candela Corporation

Brief Summary: Subjects with vulvar lichen sclerosus (VLS) will undergo fractional carbon dioxide (CO2) laser treatment to the vulvar area. Subjects will be evaluated for changes in clinical signs and architectural changes associated with VLS at designated follow-ups to 1-year post treatment series.

Detailed Description: This study is a prospective, non-randomized, single-group assignment, interventional clinical trial. Female subjects with vulvar lichen sclerosus (VLS) supported by histologic findings on biopsy and/or clinical signs on physical examination and recalcitrant to mid- to high-potency steroid therapy, will undergo up to 5 monthly treatments to the vulva with a fractional CO2 laser.

Investigators will assess clinical signs and architectural changes associated with VLS. Baseline measurements will be compared to follow-up at 6 weeks, 3 months, 6 months and 12 months after the final treatment.

Subjects will self report sexual function using a validated FSFI Questionnaire at baseline and at the 3- and 6-month follow-ups.

Recruitment & Eligibility

Status: COMPLETED

Sex: Female

Target Recruitment: 14

Inclusion Criteria

Able to read, understand and sign informed consent for study participation;
Female subjects with age 18-80 years;
Biopsy demonstrates biopsy-proven lichen sclerosus and/or there are characteristic changes for vulvar lichen sclerosus on physical examination;
Treatment of LS has been recalcitrant to mid to high-potent topical corticosteroid treatment or subject refuses topical corticosteroid treatment. Recalcitrance to therapy is defined as no response to topical corticosteroids of an adequate potency (i.e. clobetasol propionate 0.05% ointment or other steroids) and a sufficient duration (12 weeks of use) or lack of symptomatic control of the disease with a maintenance therapy;
Topical corticosteroid treatment, if any, will be continued during the study period;
Exogenous hormone treatment, if any, will be continued during the study period (type and dose must stay consistent throughout the study);
One or more of the following symptoms: itch; pain unrelated to intercourse; pain, skin tearing or bleeding with intercourse; changes/decrease in sexual function;
No breaks, tears or lesions, malodorous discharge or strawberry cervix present on gynecological exam.

Exclusion Criteria

Presence of clinically atypical appearing nevi in the area to be treated;
Unexplained vaginal bleeding;
Active infection, specifically: urinary tract infection, vulvar or vaginal infection (candidiasis, genital herpes/herpes simplex virus, bacterial vaginosis, trichomonas);
History of vulvar or any gynecological malignancy, as well as history of pelvic radiation therapy or stem cell transplant;
Pelvic organ prolapse > stage 2;
Pregnancy or planning pregnancy during the study;
Systemic treatment with immuno-modulatory drugs.
Use of vaginal dilators during study.

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
CO2RE® Treatment	The CO2RE® System	All eligible subjects will undergo up to 5 treatments at 4±1-week intervals to the vulva with a fractional CO2 laser.

Primary Outcome Measures

Name	Time	Method
Average Scores for VLS Architectural Changes Present At Baseline and at 3, 6 and 12 Months After the Last Treatment as Assessed by the Investigators	Baseline, 3 , 6 and 12 months after the final treatment	Each architectural change of VLS (labial fusion, clitoral hood fusion, narrowing of the introitus, anterior changes, perianal involvement, formation of posterior commissure bands) was assessed separately by the investigator, using a 4-point scale (0=not present, 1=mild, 2=moderate or 3=severe) for each subject at baseline and follow-ups. For those architectural changes present at baseline (baseline score \>0 on severity scale), an average severity grade was calculated at each endpoint to evaluate overall treatment outcome, as follows: Average severity grade = Sum of all severity grades (0, 1, 2, or 3) for each individual parameter of architectural changes present at baseline for each subject / Number of grades A lower average score means better outcome.
Average Scores for VLS Clinical Signs Present At Baseline, 3, 6 and 12 Months After the Last Treatment as Assessed by the Investigators	At Baseline, 3, 6 and 12 months after the final treatment	Each clinical sign of VLS (loss of elasticity, sclerosis, lichenification, whitening, parchment-like skin, fissures, extent of the disease, erosions, ulcerations, hyperkeratosis, excoriation, telangiectasia) was assessed separately by the investigator, using a 4-point scale (0=not present, 1=mild, 2=moderate or 3=severe) for each subject at baseline and follow-ups. For those clinical signs present at baseline (baseline score \>0 on severity scale), an average severity grade was calculated at each endpoint to evaluate overall treatment outcome, as follows: Average severity grade = Sum of all severity grades (0, 1, 2, or 3) for each individual parameter of clinical signs present at baseline for each subject / Number of grades A lower average score means better outcome.

Secondary Outcome Measures

Name	Time	Method
Subject Satisfaction At the 12-Month Follow-up	12 months after the final treatment	Evaluate Subject satisfaction at the 12 months post-last treatment visit, using a satisfaction scale \[(-2) Very dissatisfied, (-1) Dissatisfied, (0) Uncertain, (1) Satisfied, (2) Very satisfied\]. The analysis quantify the percentage of Subject satisfaction (score 1 or 2) at the 12-month follow-up.
Change From Baseline in Sexual Function on the Female Sexual Function Index (FSFI) at 3 Months and 6 Months After the Final Treatment	Baseline and 3 months and 6 months after the final treatment	Female Sexual Function Index (FSFI) is a validated, self-reported 19-item questionnaire that assesses domains of sexual function, including desire, arousal, lubrication, orgasm, satisfaction, and pain. The aggregated FSFI score is a sum of weighted answers for each of the 19 items in the questionnaire, with a maximum total score possible of 36.0 (high level of sexual functional) and minimum score of 2.0 (low level of sexual functional). Change = (Follow-up score - Baseline score). Mean change was calculated for all scores at the 3- and 6-month follow-ups.
Treatment Associated Pain Score	Immediately after the 1st, 2nd, 3rd, 4th and 5th monthly treatments post baseline	Subjects underwent 3-5 monthly treatments and reported discomfort associated with treatment on a 10-cm visual analogue scale (VAS) of 0 = no pain to 10 = worst possible pain, immediately after each treatment. The outcome presented here is the mean grade of discomfort/pain associated with all treatments. Lower value presents lower treatment-associated discomfort. Since patients received 3-5 monthly treatments these values were collected at each treatment over a period of 2 to 4 months for each patient.

Trial Locations

Locations (4): Center for Modern Aesthetic Medicine
🇺🇸
Jacksonville, Florida, United States
Total Dermatology Care Center
🇺🇸
Jacksonville, Florida, United States
Lumina Med Spa
🇺🇸
South Burlington, Vermont, United States
HERmd (formerly Somi Javaid M.D. & Associates)
🇺🇸
Cincinnati, Ohio, United States